DATED August [_8_], 2021 STERLING WISCONSIN, LLC and BIOSIGHT LTD. MASTER AGREEMENTMaster Agreement • October 14th, 2021 • Advaxis, Inc. • Pharmaceutical preparations • England and Wales
INDEPENDENT RESEARCH FUNDING AGREEMENTIndependent Research Funding Agreement • October 14th, 2021 • Advaxis, Inc. • Pharmaceutical preparations • London
This Independent Research Funding Agreement (this “Agreement”) is made this 15 day of July, 2020 (the “Effective Date”) by and between: Biosight Ltd. (hereinafter referred to as “COMPANY”), address 3 Ha’yarden St., Airport City, Israel; and GFM (Groupe Francophone des MyélodysplasiES (hereinafter referred to as “INSTITUTION”), located at Service d’HématologieSéniors, Hôpital Saint Louis/ Université Paris 7, 1 avenue Claude Vellefaux/ 75010 Paris, France.
AMENDMENT #1 TO THE MASTER AGREEMENT FOR CLINICAL TRIALS MANAGEMENT SERVICESThe Master Agreement • October 14th, 2021 • Advaxis, Inc. • Pharmaceutical preparations
This Amendment #1 (“Amendment”), effective as of the 20th day of November, 2020, (the “Amendment Effective Date”), by and between Pharmaceutical Research Associates, Inc., together with its Affiliates, with offices at 4130 ParkLake Avenue, Suite 400, Raleigh, NC 27612, USA (hereinafter referred to as “PRA”) and Biosight Ltd., with offices at 1 Hayarden St., Airport City, P.O.B 1083 Lod 7019802, Israel (hereinafter referred to as “Sponsor”), both hereinafter referred as “Parties”.
MASTER SERVICES AGREEMENTMaster Services Agreement • October 14th, 2021 • Advaxis, Inc. • Pharmaceutical preparations
This Master Services Agreement (“Agreement”) is made and entered into as of June 16, 2017 (the “Effective Date”), by and between Albany Molecular Research, Inc., having its principal place of business at 26 Corporate Circle, Albany, New York 12203 (together with its Affiliates hereinafter collectively referred to as “AMRI”) and BioSight Ltd., a company incorporated under the laws of Israel, having its principal place of business at 1 Hayarden St., Airport City, Lod 7019802, Israel (hereinafter “Customer”) (AMRI and Customer hereinafter referred to as “the Parties”).
Master Agreement for Clinical Trials Management ServicesAdvaxis, Inc. • October 14th, 2021 • Pharmaceutical preparations • England and Wales
This Master Agreement for Clinical Trials Management Services (the “Agreement”) is made and entered into on May 3,2018 and effective as of November 20,2017, (the “Effective Date”), by and between Biosight Ltd., an Israeli corporation, with offices at 1 Hayarden St., Airport City, P.O.B 1083 Lod 7019802, Israel (hereinafter referred to as “Sponsor”) and Pharmaceutical Research Associates, Inc., a Commonwealth of Virginia corporation, together with its Affiliates, with offices at 4130 ParkLake Avenue, Suite 400, Raleigh, NC 27612 (hereinafter referred to as “PRA”), each hereinafter referred as “Party” and both hereinafter referred as “Parties”.
Separation Agreement (the “Agreement”)Separation Agreement • October 14th, 2021 • Advaxis, Inc. • Pharmaceutical preparations
By and between Biosight Ltd., with its registered office at 3 Hayarden St., Airport City, Lod, Israel (the “Company”), and RAM Technologies (RBY 2012) Ltd. (the “CEO”) and Dr. Ruth Ben Yakar (“Dr. Ben Yakar”), dated this 7th day of October 2021.
